No Prescription |
 |
 | ||
|
TAVANIC Levaquin |
|
| ||
No Prescription » Prescription Drugs 15 » TAVANIC Levaquin Levofloxacin is used treat infections such as pneumonia; chronic bronchitis; and sinus urinary tract kidney and skin infections. Levofloxacin is in a class of antibiotics called fluoroquinolones. It works by eliminating bacteria that cause infections. Antibiotics will not work for colds flu or other viral infections. Buy TAVANIC Levaquin and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About TAVANIC Levaquin: Product Type: Prescription Drugs 15 TAVANIC ( Levaquin Generic Levofloxacin ) TAVANIC (Levaquin Generic Levofloxacin) Levaquin Generic Levofloxacin 250mg Tabs Levaquin Generic Levofloxacin TAVANIC
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
